MétaCan
Menu
← Back to cohort
Record W4390191711 · doi:10.1002/alz.082938

Clinical proteomic analysis across the Alzheimer’s disease continuum

2023· article· en· W4390191711 on OpenAlexaff
Sophia Weiner, Mathias Sauer, Nicholas J. Ashton, Andréa Lessa Benedet, Pedro Rosa‐Neto, Kaj Blennow, Henrik Zetterberg, Johan Gobom

Bibliographic record

VenueAlzheimer s & Dementia · 2023
Typearticle
Languageen
FieldMedicine
TopicAlzheimer's disease research and treatments
Canadian institutionsMcGill University Health CentreDouglas Mental Health University Institute
Fundersnot available
KeywordsDementiaBiomarkerCohortOncologyInternal medicineFrontotemporal dementiaMedicineNeuropsychologyDiseasePsychologyAlzheimer's diseaseNeuroimagingPositron emission tomographyPathologyCognitionNeuroscienceBiology

Abstract

fetched live from OpenAlex

Abstract Background Alzheimer’s disease (AD), defined by amyloid‐β (Aβ) and neurofibrillary tau tangles, can be viewed as a continuum, starting with an asymptomatic “pre‐clinical” phase that progresses to a symptomatic clinical stage characterized as mild cognitive impairment (MCI), and finally, AD dementia. Identifying biomarkers reflective of the different disease stages is important to detect individuals at risk of developing AD, to monitor disease progression and the effect of treatments, as well as to determine new therapeutic targets. Method We present data from a cross‐sectional tandem mass tag (TMT) proteomic study of cerebrospinal fluid (CSF) samples from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort (young adults (n = 22), cognitively unimpaired (n = 54), cognitively impaired (n = 26), MCI (n = 19), AD (n = 19), non‐AD (n = 16), frontotemporal dementia (n = 9); total n = 214); a highly profiled cohort across the AD continuum with clinical and neuropsychological assessments, MRI, and Aβ and tau positron emission tomography (PET). To enhance detection of brain‐derived proteins, we evaluated the use of a TMT booster channel consisting of brain protein extract. Planned statistical analyses include linear regression modelling to compare biomarker distributions across groups, covariating for sex and age where appropriate as well as correlation analyses of biomarker levels with Aβ and tau PET measurements. Result Our preliminary data analysis suggests that a set of proteins differed with high significance between amyloid PET negative and positive individuals (Fig. 1), including proteins that showed changes already at the pre‐clinical stage of AD. We will explore the correlation of the identified biomarker candidates with pathological process and disease progression, as well as with Aβ‐ and tau‐PET measurements. Also, protein changes associated with aging and other neurodegenerative disorders will be evaluated. Finally, the use of a TMT booster based on brain protein extract to enhance identification of CSF biomarkers will be assessed. Conclusion This study describes the most extensive unbiased proteomic profiling in CSF across the AD continuum, identifying proteins that may serve as novel therapeutic targets and fluid biomarkers for the disease. Additionally, the use of a TMT booster to enhance the detection of brain‐derived proteins was evaluated.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0000.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.070
GPT teacher head0.402
Teacher spread0.332 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicAlzheimer's disease research and treatments→French-language works237,207→